TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04725201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin
Description: See experimental arm description for intervention description.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: See sham comparator arm description for intervention description.
Study: NCT03981185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated theta burst treatment
Description: All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator.
Study: NCT06231030

Intervention type: OTHER
Intervention: Validity, Reliability and Adaptation
Description: Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
Study: NCT04838041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib 40 MG
Description: 40 mg by mouth (PO) when used with imatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib 40 MG Twice Daily
Description: 40 mg twice daily when used with nilotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib 80 MG daily
Description: 80 mg daily when used with dasatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Maximum dose of 400 mg PO once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Maximum dose of 300 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Maximum dose of 100 mg PO once daily.
Study: NCT05369780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Collagen Peptide
Description: Dietary Hydrolized Collagen Peptide sourced from bovine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrolyzed Collagen Peptide
Description: Dietary Hydrolized Collagen Peptide sourced from bovine
Study: NCT03549819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Oil Capsules
Description: 200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Lecithin Oil in Capsule
Description: Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
Study: NCT04078074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary OSS
Description: Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular OSS
Description: Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified farrar splint
Description: Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
Study: NCT06174116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will take placebo for 12 weeks, in addition to their regular medications.
Study: NCT06237673

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: CT-directed clinical management strategy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: invasive coronary angiography (ICA)
Description: Standard clinical management directed by conventional invasive coronary angiography (ICA).
Study: NCT06508788

Intervention type: DEVICE
Intervention: CO2 laser
Description: Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
Study: NCT06300892

Intervention type: OTHER
Intervention: No intervention
Description: samples from the incision site and GI tract collected

Intervention type: OTHER
Intervention: No intervention
Description: samples from the incision site and GI tract collected
Study: NCT04618406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO VAC
Description: PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
Study: NCT04602819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure 755nm picosecond alexandrite laser with diffractive lens
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApolloVue® S100 Image System
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutometer® dual MPA 580
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISIA®
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
Study: NCT04888728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWN12088
Description: Prolyl-tRNA synthetase (PRS) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWN12088
Description: Prolyl-tRNA synthetase (PRS) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine
Study: NCT05691712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC as add-on to the pre-trial background medication.
Study: NCT06109311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05334368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depemokimab
Description: Depemokimab will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT06053307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance commitment therapy
Description: The baseline intervention will use ACT, a psychological intervention based on modern behavioral psychology, including relational frame theory, that uses acceptance and mindfulness strategies, along with commitment and behavior-change strategies to increase psychological flexibility. The proposed intervention will be delivered over a 6-week period, with each week including content related to one of the six tenets of ACT: cognitive defusion, acceptance, contact with the present moment, the observing self, values, and committed action. Each week will include educational material, skills work, and homework. The intervention will be delivered via a mobile application.
Study: NCT06448091

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panel-based pharmacogenetic genotyping
Description: After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card
Study: NCT05103384

Intervention type: OTHER
Intervention: Virtual Reality Environment
Description: Participants complete various tasks in a virtual home and grocery store environment.
Study: NCT05392296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric hand grip strengthening exercises
Description: conventional treatment (isometric hand grip training exercises)
Study: NCT05763797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Interview
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Interview
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.
Study: NCT05530187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Patient-reported Outcomes-based Model of Care
Description: Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
Study: NCT05912348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Physical Activity and Added Carbohydrate Group
Description: Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.
Study: NCT05607641

Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
Description: These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Study: NCT05763797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Interview
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.
Study: NCT05607641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
Description: These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neospastil, solution for injection then Neospastil, film-coated tablets
Description: These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Study: NCT05325307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupressure
Description: In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
Study: NCT06189547

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history

Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history
Study: NCT05030558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-assisted patient education intervention designed according to the common-sense model
Description: Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
Description: The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
Study: NCT05763797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Exercise
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Exercise
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Exercise
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.
Study: NCT04240054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
Study: NCT04775186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
Description: Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
Description: Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)